Lysosomal storage disorders affecting the heart: a review

Cardiovascular Pathology

Volumn 39, Issue , 2019, Pages 12-24

  Nair, Vidhya ^a   Belanger, Eric C ^a   Veinot, John P ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Fabry Disease; Lysosomal storage disorders; Mucopolysaccharidosis; Pompe Disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA GLUCURONIDASE; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDE; GLYCOSAMINOGLYCAN; HYALURONIDASE; HYDROXYCHLOROQUINE; LEVO IDURONIDASE; LYSOSOME ENZYME; N ACETYLGALACTOSAMINE 4 SULFATASE; N ACETYLGALACTOSAMINE 6 SULFATASE; N SULFOGLUCOSAMINE SULFOHYDROLASE; OLIGOSACCHARIDE; SPHINGOMYELIN PHOSPHODIESTERASE; VIRUS VECTOR;

AORTIC RECONSTRUCTION; BIOCHEMICAL ANALYSIS; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DANON DISEASE; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME REPLACEMENT; EPIDEMIOLOGICAL DATA; FABRY DISEASE; GAUCHER DISEASE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GLYCOGEN STORAGE DISEASE TYPE 2; GROUPS BY AGE; HEART DISEASE; HEART MUSCLE BIOPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; INHERITANCE; LIPIDOSIS; LYSOSOME STORAGE DISEASE; MITRAL VALVE REPAIR; MOLECULAR GENETICS; MUCOPOLYSACCHARIDOSIS; NIEMANN PICK DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ROSS PROCEDURE; SCREENING; SYSTEMIC THERAPY; ULTRASTRUCTURE; VALVULAR HEART DISEASE; VIRAL GENE THERAPY; WOLFF PARKINSON WHITE SYNDROME; BIOPSY; CARDIAC MUSCLE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PHENOTYPE; RISK FACTOR; TREATMENT OUTCOME;

BIOPSY; ENZYME REPLACEMENT THERAPY; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES; HUMANS; LYSOSOMAL STORAGE DISEASES; MYOCARDIUM; PHENOTYPE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85059088565     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2018.11.002     Document Type: Review

References (67)

1. Linhart, A., Elliott, P. M., The heart in Anderson–Fabry disease and other lysosomal storage disorders. Heart 93:4 (2007), 528–535 [Review. PubMed PMID: 17401074; PubMed Central PMCID: PMC1861503].
2. de Duve, C., The lysosome turns fifty. Nat Cell Biol 7:9 (2005), 847–849, 10.1038/ncb0905-847 [PMID 16136179].
3. Hicks, J., Wartchow, E., Mierau, G., Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol 35:5 (2011), 183–196, 10.3109/01913123.2011.601404 [Review. PubMed PMID: 21910565].
4. Kroos, M., Pomponio, R. J., van Vliet, L., Palmer, R. E., Phipps, M., Van der Helm, R., et al. Reuser A; GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29:6 (2008), E13–E26, 10.1002/humu.20745 [PubMed PMID: 18425781].
5. Lim, J. A., Li, L., Raben, N., Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci, 6, 2014, 177, 10.3389/fnagi.2014.00177 [eCollection 2014. Review. PubMed PMID: 25183957; PubMed Central PMCID: PMC4135233].
6. Dasouki, M., Jawdat, O., Almadhoun, O., Pasnoor, M., McVey, A. L., Abuzinadah, A., et al. Pompe disease: literature review and case series. Neurol Clin 32:3 (2014), 751–776, ix, 10.1016/j.ncl.2014.04.010 [Review. PubMed PMID: 25037089; PubMed Central PMCID: PMC4311397].
7. Chien, Y. H., Hwu, W. L., Lee, N. C., Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 54:4 (2013), 219–227, 10.1016/j.pedneo.2013.03.009 [Epub 2013 Apr 28. Review. PubMed PMID: 23632029].
8. Raben, N., Plotz, P., Byrne, B. J., Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2:2 (2002), 145–166 [Review. PubMed PMID: 11949932].
9. Wenger NK, Goodwin JF, Roberts WC. Cardiomyopathy and myocardial involvement in systemic disease. In: Hurst WH, editor in chief, Logue RB, Rackely CE, Schlant RC, Sonenblick EH, Wallace AG, Wenger NK, editors. Hurst's the heart, 6th ed: McGraw Hill Book Company; 1986, p.1181–1249.
10. Mazzitello, W. F., Briggs, J. F., Glycogen storage disease of the myocardium. Dis Chest 32:6 (1957), 636–645 [PubMed PMID: 13480207].
11. Kroos, M., Hoogeveen-Westerveld, M., van der Ploeg, A., Reuser, A. J., The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:1 (2012), 59–68, 10.1002/ajmg.c.31318 [Epub 2012 Jan 17. Review. PubMed PMID: 22253258].
12. Lester, Wanda M., Avrum, I., Cardiovascular effects of systemic diseases and conditions. Silver, Malcolm, Gotlieb, Avrum I., Schoen, Frederick R., (eds.) Cardiovascular pathology, 3rd ed., 2001, Churchill Livingston, Pennyslvannia, 493–540.
13. Ghadially, F. N., Lysosomes. Ghadially, Feroze N., (eds.) Ultrastructural pathology of the cell and matrix, volume 2, 4th ed., 1997, Butterworth- Heineman, Masschussets.
14. Bodamer, O. A., Scott, C. R., Giugliani, R., Pompe Disease Newborn Screening Working Group, Newborn screening for Pompe disease. Pediatrics 140:Suppl.1 (2017), S4–S13, 10.1542/peds.2016-0280C [PubMed PMID: 29162673].
15. Bottillo, I., Giordano, C., Cerbelli, B., D'Angelantonio, D., Lipari, M., Polidori, T., et al. A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. Cardiovasc Pathol 25:5 (2016), 423–431, 10.1016/j.carpath.2016.07.005 [Epub 2016 Jul 25. Review. PubMed PMID: 27497751].
16. D'souza, R. S., Mestroni, L., Taylor, M. R. G., Danon disease for the cardiologist: case report and review of the literature. J Community Hosp Intern Med Perspect 7:2 (2017), 107–114, 10.1080/2000966620171324239 [eCollection 2017 Mar. PubMed PMID: 28638575; PubMed Central PMCID: PMC5473185].
17. Danon, M. J., Oh, S. J., DiMauro, S., et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 31 (1981), 51–57.
18. Di Mauro, S., Tanji, K., Hirano, M., LAMP-2 deficiency (Danon disease). Acta Myol 26:1 (2007), 79–82 [PubMed PMID: 17915578; PubMed Central PMCID: PMC2949328].
19. Stokes, M. B., Taylor, A. J., McLean, C. A., D'Arcy, C. E., Mariani, J. A., Severe left ventricular hypertrophy and marked cardiac fibrosis in Danon disease. Int J Cardiol 221 (2016), 14–16, 10.1016/j.ijcard.2016.06.311 [Epub 2016 Jul1. PubMed PMID: 27395820].
20. Yang, Z., Vatta, M., Danon disease as a cause of autophagic vacuolar myopathy. Congenit Heart Dis 2:6 (2007), 404–409, 10.1111/j.1747-0803.2007.00132.x [Review. PubMed PMID: 18377432].
21. Butany, Jagdish, Ibrahim, Amir, LAMP2 mutation (Danon DISEASE). Miller, D. V., Revelo, M. P., (eds.) Diagnostic pathology cardiovascular, 2014, Amirsys Inc., Manitoba, 1–20.
22. Soliman, O. I., Timmermans, R. G., Nemes, A., Vletter, W. B., Wilson, J. H., ten Cate, F. J., et al. Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis 30:5 (2007), 750–757 [Epub 2007 Jun 14. PubMed PMID: 17574537; PubMed Central PMCID: PMC2798132].
23. Braunlin, E. A., Harmatz, P. R., Scarpa, M., Furlanetto, B., Kampmann, C., Loehr, J. P., et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 34:6 (2011), 1183–1197, 10.1007/s10545-011-9359-8 [Epub 2011 Jul 9.Review. PubMed PMID: 21744090; PubMed Central PMCID: PMC3228957].
24. Dangel, J. H., Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders — clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157 (1998), 534–538.
25. Fesslová V., Corti, P., Sersale, G., et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19 (2009), 170–178.
26. Tan, C. T. T., Schaff, H. V., Miller, F. A., Edwards, W. D., Karnes, P. S., Valvular heart disease in four patients with Maroteaux–Lamy syndrome. Circulation 85 (1992), 188–195.
27. Renteria, V. G., Ferrans, V. J., Roberts, W. C., The heart in the Hurler syndrome. Gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 38 (1976), 487–501.
28. Braunlin, E., Orchard, P. J., Whitley, C. B., Schroeder, L., Reed, R. C., Manivel, J. C., Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review. Cardiovasc Pathol 23:3 (2014), 145–151, 10.1016/j.carpath.2014.01.001 [Epub 2014 Jan 10. Review. PubMed PMID: 24508139].
29. Bolourchi, M., Renella, P., Wang, R. Y., Aortic root dilatation in mucopolysaccharidosis I– VII. Int J Mol Sci, 17(12), 2016 [pii: E2004. PubMed PMID: 27916847; PubMed Central PMCID: PMC5187804].
30. Hobbs, J. R., Hugh-Jones, K., Barrett, A. J., Byrom, N., Chambers, D., Henry, K., et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2:8249 (1981), 709–712 [PubMed PMID: 6116856].
31. Penati, R., Fumagalli, F., Calbi, V., Bern ardo, M. E., Aiuti, A., Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis 40:4 (2017), 543–554, 10.1007/s10545-017-0052-4 [Epub 2017 May 30. Review. PubMed PMID: 28560469; PubMed Central PMCID: PMC5500670].
32. Torloni, M. R., Franco, K., Sass, N., Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med J 120:3 (2002), 90–92 [PubMed PMID: 12163901].
33. Veinot, J. P., Elstein, D., Hanania, D., Abrahamov, A., Srivatsa, S., Zimran, A., Gaucher's disease with valve calcification: possible role of Gaucher cells, bone matrix proteins and integrins. Can J Cardiol 15:2 (1999), 211–216 [PubMed PMID: 10079781].
34. Kahn, P., Anderson–Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 36:6 (1973), 1053–1062 [PubMed PMID: 4204059; PubMed Central PMCID: PMC1083608].
35. Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:4 (2003), 338–346 [Review. PubMed PMID: 12585833].
36. Frustaci, A., Morgante, E., Russo, M. A., Scopelliti, F., Grande, C., Verardo, R., et al. Pathology and function of conduction tissue in Fabry disease cardiomyopathy. Circ Arrhythm Electrophysiol 8:4 (2015), 799–805, 10.1161/CIRCEP.114.002569 [Epub 2015 Jun 5. PubMed PMID: 26047621].
37. Putko, B. N., Wen, K., Thompson, R. B., Mullen, J., Shanks, M., Yogasundaram, H., et al. Anderson–Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev 20:2 (2015), 179–191, 10.1007/s10741-014-9452-9 [Review. PubMed PMID: 25030479].
38. Grunfeld, J. P., Lidove, O., Joly, D., Barbey, F., Renal disease in Fabry patients. J Inherit Metab Dis 24:Suppl. 2 (2001), 71–74.
39. Linhart, A., Lubanda, J. C., Palecek, T., Bultas, J., Karetova, D., Led- vinova, J., et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24:Suppl. 2 (2001), 75–83.
40. Tuttolomondo, A., Pecoraro, R., Simonetta, I., Miceli, S., Arnao, V., Licata, G., et al. Neurological complications of Anderson–Fabry disease. Curr Pharm Des 19 (2013), 6014–6030.
41. Shah, J. S., Elliott, P. M., Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr Suppl 94:447 (2005), 11–14 [discussion 9-10. Review. PubMed PMID: 15895705].
42. Perrot, A., Osterziel, K. J., Beck, M., Dietz, R., Kampmann, C., Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz 27:7 (2002), 699–702 [PubMed PMID: 12439642].
43. Yogasundaram, H., Kim, D., Oudit, O., Thompson, R. B., Weidemann, F., Oudit, G. Y., Clinical features, diagnosis, and management of patients with Anderson–Fabry cardiomyopathy. Can J Cardiol 33:7 (2017), 883–897, 10.1016/j.cjca.2017.04.015 [Epub 2017 May 4. Review. PubMed PMID: 28668140].
44. Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:9 (2006), 539–548 [Review. PubMed PMID: 16980809].
45. Beck, M., Hughes, D., Kampmann, C., Larroque, S., Mehta, A., Pintos-Morell, G., et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis. Mol Genet Metab Rep 3 (2015), 21–27, 10.1016/j.ymgmr.2015.02.002 [eCollection 2015 Jun. PubMed PMID: 26937390; PubMed Central PMCID: PMC4750577].
46. Yogasundaram, H., Putko, B. N., Tien, J., Paterson, D. I., Cujec, B., Ringrose, J., et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 30:12 (2014), 1706–1715, 10.1016/j.cjca.2014.08.016 [Epub 2014 Aug 23. Review. PubMed PMID: 25475472].
47. Dogar, M. U., Shah, N. N., Ishtiaq, S., Shah, P. N., Shah, P., Mathew, S., et al. Hydroxychloroquine-induced restrictive cardiomyopathy: a case report. Postgrad Med J 94:1109 (2018), 185–186, 10.1136/postgradmedj-2017-135236 [Epub 2018 Jan 20. PubMed PMID: 29353247].
48. Arad, M., Benson, D. W., Perez-Atayde, A. R., McKenna, W. J., Sparks, E. A., Kanter, R. J., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109:3 (2002), 357–362 [PubMed PMID: 11827995; PubMed Central PMCID: PMC150860].
49. Banankhah, P., Fishbein, G. A., Dota, A., Ardehali, R., Cardiac manifestations of PRKAG2 mutation. BMC Med Genet, 19(1), 2018, 1, 10.1186/s12881-017-0512-6 [PubMed PMID: 29298659; PubMed Central PMCID: PMC5751825].
50. Meyers, D. E., Basha, H. I., Koenig, M. K., Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Tex Heart Inst J 40:4 (2013), 385–394 [Review. PubMed PMID: 24082366; PubMed Central PMCID: PMC3783139].
51. Arbustini, E., Diegoli, M., Fasani, R., Grasso, M., Morbini, P., Banchieri, N., et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol 153:5 (1998), 1501–1510 [PubMed PMID: 9811342;PubMed Central PMCID: PMC1853408].
52. Marian, A. J., Braunwald, E., Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:7 (2017), 749–770, 10.1161/CIRCRESAHA.117.311059 [. Review. PubMed PMID: 28912181; PubMed Central PMCID: PMC5654557].
53. Ho, C. Y., Hypertrophic cardiomyopathy: preclinical and early phenotype. J Cardiovasc Transl Res 2:4 (2009), 462–470, 10.1007/s12265-009-9124-7 [Epub 2009 Sep 26. Review. Erratum in: J Cardiovasc Transl Res. 2013 Aug;6(4):662. PubMed PMID: 20560004].
54. Hughes, S. E., The pathology of hypertrophic cardiomyopathy. Histopathology 44:5 (2004), 412–427 [Review. PubMed PMID: 15139989].
55. Teekakirikul, P., Kelly, M. A., Rehm, H. L., Lakdawala, N. K., Funke, B. H., Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn 15:2 (2013), 158–170, 10.1016/j.jmoldx.2012.09.002 [Epub 2012 Dec 27. Review. PubMed PMID: 23274168].
56. Nishimura, R. A., Seggewiss, H., Schaff, H. V., Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation. Circ Res 121:7 (2017), 771–783, 10.1161/CIRCRESAHA.116.309348 [Review. PubMed PMID: 28912182].
57. Bekri, S., Laboratory diagnosis of lysosomal storage diseases. Mehta, A., Beck, M., Sunder-Plassmann, G., (eds.) Fabry disease: perspectives from 5 years of FOS, 2006, Oxford PharmaGenesis, Oxford [Chapter 8].
58. Meikle, P. J., Ranieri, E., Simonsen, H., Rozaklis, T., Ramsay, S. L., Whitfield, P. D., et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 114 (2004), 909–916.
59. Humbel, R., Collart, M., Oligosaccharides in urine of patients with glycoprotein storage diseases. I. Rapid detection by thin-layer chromatography. Clin Chim Acta 60 (1975), 143–145.
60. Ramsay, S. L., Maire, I., Bindloss, C., Fuller, M., Whitfield, P. D., Piraud, M., et al. Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in uteroindicators of lysosomal storage diseases. Mol Genet Metab 83 (2004), 231–238.
61. Conzelmann, E., Sandhoff, K., Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6 (1983), 58–71.
62. Taniguchi, N., Kato, E., Yoshida, H., Iwaki, S., Ohki, T., Koizumi, S., Alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state. Clin Chim Acta, 89, 1978, 293e9.
63. Shin, Y. S., Endres, W., Unterreithmeier, J., Rieth, M., Schaub, J., Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-alpha-glucosidase in human fetal and adult tissues and cultured cells. Clin Chim Acta, 148, 1985, 9e19.
64. Umapathysivam, K., Whittle, A. M., Ranieri, E., Bindloss, C., Ravenscroft, E. M., van Diggelen, O. P., et al. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem, 46, 2000, 1318e25.
65. Filocamo, M., Morrone, A., Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics., 5(3), 2011, 156–169 [Review. PubMed PMID: 21504867; PubMed Central PMCID: PMC3500170].
66. Parenti, G., Pignata, C., Vajro, P., Salerno, M., New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 31:1 (2013), 11–20, 10.3892/ijmm.2012.1187 [Epub 2012 Nov 19. Review. PubMed PMID: 23165354].
67. Macauley, S. L., Combination therapies for lysosomal storage diseases: a complex answer to a simple problem. Pediatr Endocrinol Rev 13:Suppl. 1 (2016), 639–648 [Review. PubMed PMID: 27491211; PubMed Central PMCID: PMC5374980].